LIVIVO - Search results -

Search results

Result 1 - 7 of total 7

Search options

Article: The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.

Wang, Hao / Berger, Kristin N / Miller, Elizabeth L / Fu, Wei / Broglie, Larisa / Goldman, Frederick D / Konig, Heiko / Lim, Su Jin / Berg, Arthur S / Talano, Julie-An / Comito, Melanie A / Farag, Sherif S / Pu, Jeffrey J

Therapeutic advances in hematology

2023 Volume 14, Page(s) 20406207231170708

Abstract: Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of ... ...

Abstract	Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown. Objectives: The aim of this study was to evaluate the impacts of TBI on UCBT outcomes. Design: This was a multi-institution retrospective study. Methods: A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively. Results: In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI. Conclusion: In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.
Language	English
Publishing date	2023-05-03
Publishing country	England
Document type	Journal Article
ZDB-ID	2585183-4
ISSN	2040-6215 ; 2040-6207
ISSN (online)	2040-6215
ISSN	2040-6207
DOI	10.1177/20406207231170708
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Attributable costs of central line-associated bloodstream infections in a pediatric hematology/oncology population.

Wilson, Matthew Z / Rafferty, Colleen / Deeter, Deana / Comito, Melanie A / Hollenbeak, Christopher S

American journal of infection control

2014 Volume 42, Issue 11, Page(s) 1157–1160

Abstract: Background: Although several studies have estimated the attributable cost and length of stay (LOS) of central line-associated bloodstream infections (CLABSIs) in the pediatric intensive care unit setting, little is known about the attributable costs and ...

Abstract	Background: Although several studies have estimated the attributable cost and length of stay (LOS) of central line-associated bloodstream infections (CLABSIs) in the pediatric intensive care unit setting, little is known about the attributable costs and LOS of CLABSIs in the vulnerable pediatric hematology/oncology population. Methods: We studied a total of 1562 inpatient admissions for 291 pediatric hematology/oncology patients at a single tertiary care children's hospital in the mid-Atlantic region between January 2008 and May 2011. Costs were normalized to year 2011 dollars. Propensity score matching was used to estimate the effect of CLABSIs on total cost and LOS while controlling for other covariates. Results: Sixty CLABSIs occurred during the 1562 admissions. Compared with the patients without a CLABSI, those who developed a CLABSI tended to be older (9.0 years vs 7.5 years; P = .026) and to have a tunneled catheter (46.7% vs 27.0%) and a peripherally inserted central catheter (20.0% vs 11.2%) as opposed to other types of catheters (P < .0001). Propensity score matching yielded matched groups without significant differences in patient characteristics. In the propensity score analysis, the attributable LOS of a CLABSI was 21.2 days (P < .0001), and the attributable cost of a CLABSI was $69,332 (P < .0001). Conclusions: Among pediatric hematology/oncology patients, CLABSI was associated with an additional LOS of 21 days and increased costs of nearly $70,000. These findings may inform decisions regarding the value of investing in efforts to prevent CLABSIs in this vulnerable population.
MeSH term(s)	Adolescent ; Catheter-Related Infections/economics ; Catheter-Related Infections/epidemiology ; Child ; Child, Preschool ; Female ; Health Care Costs ; Hematologic Neoplasms/complications ; Humans ; Infant ; Infant, Newborn ; Length of Stay ; Male ; Sepsis/economics ; Sepsis/epidemiology ; Tertiary Care Centers ; United States/epidemiology
Language	English
Publishing date	2014-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	392362-9
ISSN	1527-3296 ; 0196-6553
ISSN (online)	1527-3296
ISSN	0196-6553
DOI	10.1016/j.ajic.2014.07.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1773: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.

Richardson, Timothy E / Tang, Karen / Vasudevaraja, Varshini / Serrano, Jonathan / William, Christopher M / Mirchia, Kanish / Pierson, Christopher R / Leonard, Jeffrey R / AbdelBaki, Mohamed S / Schieffer, Kathleen M / Cottrell, Catherine E / Tovar-Spinoza, Zulma / Comito, Melanie A / Boué, Daniel R / Jour, George / Snuderl, Matija

Journal of neuropathology and experimental neurology

2019 Volume 78, Issue 12, Page(s) 1089–1099

Abstract: ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion ... ...

Abstract	ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion events are important findings in these tumors, as they are potentially targetable alterations with newer tyrosine kinase inhibitors; however, whether these tumors represent a distinct entity remains unknown. In this report, we identify 3 cases of unusual pediatric glioma with GOPC-ROS1 fusion. We reviewed the clinical history, radiologic and histologic features, performed methylation analysis, whole genome copy number profiling, and next generation sequencing analysis for the detection of oncogenic mutation and fusion events to fully characterize the genetic and epigenetic alterations present in these tumors. Two of 3 tumors showed pilocytic features with focal expression of synaptophysin staining and variable high-grade histologic features; the third tumor aligned best with glioblastoma and showed no evidence of neuronal differentiation. Copy number profiling revealed chromosome 6q22 microdeletions corresponding to the GOPC-ROS1 fusion in all 3 cases and methylation profiling showed that the tumors did not cluster together as a single entity or within known methylation classes by t-Distributed Stochastic Neighbor Embedding.
MeSH term(s)	Adaptor Proteins, Signal Transducing/genetics ; Brain/pathology ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Carcinogenesis ; Child ; Child, Preschool ; Chromosome Deletion ; Chromosomes, Human, Pair 6/genetics ; DNA Methylation ; Epigenesis, Genetic ; Female ; Glioma/genetics ; Glioma/pathology ; Golgi Matrix Proteins/genetics ; Humans ; Male ; Oncogene Proteins, Fusion/genetics ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics
Chemical Substances	Adaptor Proteins, Signal Transducing ; GOPC protein, human ; Golgi Matrix Proteins ; Oncogene Proteins, Fusion ; Proto-Oncogene Proteins ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; ROS1 protein, human (EC 2.7.10.1)
Language	English
Publishing date	2019-10-11
Publishing country	England
Document type	Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3088-0
ISSN	1554-6578 ; 0022-3069
ISSN (online)	1554-6578
ISSN	0022-3069
DOI	10.1093/jnen/nlz093
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.134: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Ui II Zs.194: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunotherapy for Epstein-Barr virus-associated tumors.

Comito, Melanie A / Sun, Qi / Lucas, Kenneth G

Leukemia & lymphoma

2004 Volume 45, Issue 10, Page(s) 1981–1987

Abstract: Epstein-Barr Virus (EBV) is associated with a number of tumors, including lymphomas in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, patients with the acquired immunodeficiency syndrome (AIDS), Burkitt's lymphoma, ...

Abstract	Epstein-Barr Virus (EBV) is associated with a number of tumors, including lymphomas in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, patients with the acquired immunodeficiency syndrome (AIDS), Burkitt's lymphoma, as well as a subset of patients with nasopharyngeal carcinoma (NPC) and Hodgkin's disease (HD). The types of latent EBV infections vary in these tumors, which influences the EBV antigens expressed and ultimately the immunogenicity of tumor cells. Not all EBV associated malignancies are directly related to altered cellular immunity, as is the case with EBV induced lymphoproliferations in immunocompromised patients. Treatment strategies have ranged from restoration of normal cellular immunity, which is generally successful in SOT and HSCT patients, anti-B cell monoclonal antibodies, and conventional chemotherapy and radiation. The fact that these tumors express EBV antigens for which many individuals have high circulating levels of protective cytotoxic T lymphocytes (CTL) has lead to investigation into the applicability of adoptive transfer of EBV specific T cells. Initial success with adoptive immunotherapy for HSCT and SOT patients has lead to current studies examining the feasibility and efficacy of this strategy for other EBV associated tumors, such as NPC and HD. We will review the pathogenesis of these disorders, current therapies, and future investigations aimed at targeting EBV antigen expression on these tumors.
MeSH term(s)	Antigens, Viral/immunology ; Antigens, Viral/therapeutic use ; Herpesvirus 4, Human/immunology ; Humans ; Immunotherapy, Adoptive/methods ; Lymphoma/therapy ; Lymphoma/virology ; Neoplasms/therapy ; Neoplasms/virology ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Cytotoxic/transplantation ; Transplantation
Chemical Substances	Antigens, Viral
Language	English
Publishing date	2004-04-16
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428190410001700831
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Idiopathic thrombocytopenic purpura complicated by an intracranial hemorrhage secondary to an arteriovenous malformation.

Downs, Lorrie A / Thomas, Neal J / Comito, Melanie A / Meier, Andreas H / Dias, Mark S

Pediatric emergency care

2005 Volume 21, Issue 5, Page(s) 309–311

Abstract: Objective: To report a case of idiopathic thrombocytopenic purpura (ITP) complicated by an intracranial hemorrhage (ICH) in a child with a previously undiagnosed arteriovenous malformation.: Case: We describe a child with known ITP who developed a ... ...

Abstract	Objective: To report a case of idiopathic thrombocytopenic purpura (ITP) complicated by an intracranial hemorrhage (ICH) in a child with a previously undiagnosed arteriovenous malformation. Case: We describe a child with known ITP who developed a severe headache, was evaluated in an emergency department of a community hospital, and was found by computer tomography (CT) scan to have an ICH. Despite treatment with platelets, corticosteroids, and intravenous immunoglobulin, she subsequently developed an acute change in mental status. A second CT scan showed that the hemorrhage had significantly increased in size despite treatment. The patient underwent an emergent splenectomy prior to a craniotomy to remove the hemorrhage. At the time of surgery, it was discovered that she had an arteriovenous malformation at the sight of the hemorrhage. Her recovery was unremarkable and she was discharged to home with no neurologic sequelae. Conclusions: ICH is a rare but life-threatening complication of ITP. Neurologic symptoms in a child with ITP should be quickly evaluated by CT scan. Most experts suggest careful observation for most cases of ITP. However, when neurologic symptoms occur, more aggressive treatment options must be used. Care of this child included an emergency splenectomy prior to her craniotomy. Pediatric emergency medicine practitioners must be aware of these neurologic symptoms and must not hesitate to involve pediatric surgeons and neurosurgeons in the care of the child. Prompt recognition and early intervention are the keys to improving outcomes when ICH complicates ITP.
MeSH term(s)	Child ; Female ; Humans ; Intracranial Arteriovenous Malformations/complications ; Intracranial Arteriovenous Malformations/therapy ; Intracranial Hemorrhages/etiology ; Intracranial Hemorrhages/therapy ; Purpura, Thrombocytopenic, Idiopathic/complications ; Purpura, Thrombocytopenic, Idiopathic/therapy
Language	English
Publishing date	2005-04-09
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	632588-9
ISSN	1535-1815 ; 0749-5161
ISSN (online)	1535-1815
ISSN	0749-5161
DOI	10.1097/01.pec.0000168988.38256.d1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2083: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.

Ercan, Ayse Bahar / Aronson, Melyssa / Fernandez, Nicholas R / Chang, Yuan / Levine, Adrian / Liu, Zhihui Amy / Negm, Logine / Edwards, Melissa / Bianchi, Vanessa / Stengs, Lucie / Chung, Jiil / Al-Battashi, Abeer / Reschke, Agnes / Lion, Alex / Ahmad, Alia / Lassaletta, Alvaro / Reddy, Alyssa T / Al-Darraji, Amir F / Shah, Amish C /

Van Damme, An / Bendel, Anne / Rashid, Aqeela / Margol, Ashley S / Kelly, Bethany L / Pencheva, Bojana / Heald, Brandie / Lemieux-Anglin, Brianna / Crooks, Bruce / Koschmann, Carl / Gilpin, Catherine / Porter, Christopher C / Gass, David / Samuel, David / Ziegler, David S / Blumenthal, Deborah T / Kuo, Dennis John / Hamideh, Dima / Basel, Donald / Khuong-Quang, Dong-Anh / Stearns, Duncan / Opocher, Enrico / Carceller, Fernando / Baris Feldman, Hagit / Toledano, Helen / Winer, Ira / Scheers, Isabelle / Fedorakova, Ivana / Su, Jack M / Vengoechea, Jaime / Sterba, Jaroslav / Knipstein, Jeffrey / Hansford, Jordan R / Gonzales-Santos, Julieta Rita / Bhatia, Kanika / Bielamowicz, Kevin J / Minhas, Khurram / Nichols, Kim E / Cole, Kristina A / Penney, Lynette / Hjort, Magnus Aasved / Sabel, Magnus / Gil-da-Costa, Maria Joao / Murray, Matthew J / Miller, Matthew / Blundell, Maude L / Massimino, Maura / Al-Hussaini, Maysa / Al-Jadiry, Mazin F / Comito, Melanie A / Osborn, Michael / Link, Michael P / Zapotocky, Michal / Ghalibafian, Mithra / Shaheen, Najma / Mushtaq, Naureen / Waespe, Nicolas / Hijiya, Nobuko / Fuentes-Bolanos, Noemi / Ahmad, Olfat / Chamdine, Omar / Roy, Paromita / Pichurin, Pavel N / Nyman, Per / Pearlman, Rachel / Auer, Rebecca C / Sukumaran, Reghu K / Kebudi, Rejin / Dvir, Rina / Raphael, Robert / Elhasid, Ronit / McGee, Rose B / Chami, Rose / Noss, Ryan / Tanaka, Ryuma / Raskin, Salmo / Sen, Santanu / Lindhorst, Scott / Perreault, Sebastien / Caspi, Shani / Riaz, Shazia / Constantini, Shlomi / Albert, Sophie / Chaleff, Stanley / Bielack, Stefan / Chiaravalli, Stefano / Cramer, Stuart Louis / Roy, Sumita / Cahn, Suzanne / Penna, Suzanne / Hamid, Syed Ahmer / Ghafoor, Tariq / Imam, Uzma / Larouche, Valerie / Magimairajan Issai, Vanan / Foulkes, William D / Lee, Yi Yen / Nathan, Paul C / Maruvka, Yosef E / Greer, Mary-Louise C / Durno, Carol / Shlien, Adam / Ertl-Wagner, Birgit / Villani, Anita / Malkin, David / Hawkins, Cynthia / Bouffet, Eric / Das, Anirban / Tabori, Uri

The Lancet. Oncology

2024 Volume 25, Issue 5, Page(s) 668–682

Abstract: Background: Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes, we aimed to describe the ...

Abstract	Background: Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes, we aimed to describe the clinical spectrum, cancer biology, and impact of genetics on patient survival in CMMRD. Methods: In this cohort study, we collected cross-sectional and longitudinal data on all patients with CMMRD, with no age limits, registered with the International Replication Repair Deficiency Consortium (IRRDC) across more than 50 countries. Clinical data were extracted from the IRRDC database, medical records, and physician-completed case record forms. The primary objective was to describe the clinical features, cancer spectrum, and biology of the condition. Secondary objectives included estimations of cancer incidence and of the impact of the specific mismatch-repair gene and genotype on cancer onset and survival, including after cancer surveillance and immunotherapy interventions. Findings: We analysed data from 201 patients (103 males, 98 females) enrolled between June 5, 2007 and Sept 9, 2022. Median age at diagnosis of CMMRD or a related cancer was 8·9 years (IQR 5·9-12·6), and median follow-up from diagnosis was 7·2 years (3·6-14·8). Endogamy among minorities and closed communities contributed to high homozygosity within countries with low consanguinity. Frequent dermatological manifestations (117 [93%] of 126 patients with complete data) led to a clinical overlap with neurofibromatosis type 1 (35 [28%] of 126). 339 cancers were reported in 194 (97%) of 201 patients. The cumulative cancer incidence by age 18 years was 90% (95% CI 80-99). Median time between cancer diagnoses for patients with more than one cancer was 1·9 years (IQR 0·8-3·9). Neoplasms developed in 15 organs and included early-onset adult cancers. CNS tumours were the most frequent (173 [51%] cancers), followed by gastrointestinal (75 [22%]), haematological (61 [18%]), and other cancer types (30 [9%]). Patients with CNS tumours had the poorest overall survival rates (39% [95% CI 30-52] at 10 years from diagnosis; log-rank p<0·0001 across four cancer types), followed by those with haematological cancers (67% [55-82]), gastrointestinal cancers (89% [81-97]), and other solid tumours (96% [88-100]). All cancers showed high mutation and microsatellite indel burdens, and pathognomonic mutational signatures. MLH1 or MSH2 variants caused earlier cancer onset than PMS2 or MSH6 variants, and inferior survival (overall survival at age 15 years 63% [95% CI 55-73] for PMS2, 49% [35-68] for MSH6, 19% [6-66] for MLH1, and 0% for MSH2; p<0·0001). Frameshift or truncating variants within the same gene caused earlier cancers and inferior outcomes compared with missense variants (p<0·0001). The greater deleterious effects of MLH1 and MSH2 variants as compared with PMS2 and MSH6 variants persisted despite overall improvements in survival after surveillance or immune checkpoint inhibitor interventions. Interpretation: The very high cancer burden and unique genomic landscape of CMMRD highlight the benefit of comprehensive assays in timely diagnosis and precision approaches toward surveillance and immunotherapy. These data will guide the clinical management of children and patients who survive into adulthood with CMMRD. Funding: The Canadian Institutes for Health Research, Stand Up to Cancer, Children's Oncology Group National Cancer Institute Community Oncology Research Program, Canadian Cancer Society, Brain Canada, The V Foundation for Cancer Research, BioCanRx, Harry and Agnieszka Hall, Meagan's Walk, BRAINchild Canada, The LivWise Foundation, St Baldrick Foundation, Hold'em for Life, and Garron Family Cancer Center.
MeSH term(s)	Humans ; Male ; Female ; Child ; Child, Preschool ; Neoplastic Syndromes, Hereditary/genetics ; Neoplastic Syndromes, Hereditary/therapy ; Cross-Sectional Studies ; Adolescent ; Brain Neoplasms/genetics ; Brain Neoplasms/therapy ; Brain Neoplasms/mortality ; Brain Neoplasms/pathology ; Brain Neoplasms/epidemiology ; DNA Mismatch Repair ; Longitudinal Studies ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/mortality ; Incidence ; MutS Homolog 2 Protein/genetics ; MutL Protein Homolog 1/genetics ; Adult ; Young Adult ; Mutation ; DNA-Binding Proteins
Chemical Substances	MutS Homolog 2 Protein (EC 3.6.1.3) ; MutL Protein Homolog 1 (EC 3.6.1.3) ; MLH1 protein, human ; MSH2 protein, human (EC 3.6.1.3) ; G-T mismatch-binding protein ; DNA-Binding Proteins
Language	English
Publishing date	2024-03-26
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Multicenter Study
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(24)00026-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾

Article ; Online: A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Pediatric blood & cancer

2013 Volume 61, Issue 4, Page(s) 636–642

Abstract: Background: Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors. We undertook a prospective, open-label, single-arm, multi-institutional phase II study to ... ...

Abstract	Background: Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors. We undertook a prospective, open-label, single-arm, multi-institutional phase II study to evaluate the efficacy of a "5-drug" oral regimen in children with recurrent or progressive cancer. Procedure: Patients ≤21 years old with recurrent or progressive tumors were eligible. Treatment consisted of continuous oral celecoxib, thalidomide, and fenofibrate, with alternating 21-day cycles of low-dose cyclophosphamide and etoposide. Primary endpoint was to assess, within eight disease strata, activity of the 5-drug regimen over 27 weeks. Blood and urine angiogenesis markers were assessed. Results: One hundred one patients were enrolled; 97 began treatment. Median age was 10 years (range: 191 days-21 years); 47 (49%) were female. Disease strata included high-grade glioma (HGG, 21 patients), ependymoma (19), low-grade glioma (LGG, 12), bone tumors (12), medulloblastoma/primitive neuroectodermal tumor (PNET, 8), leukemia (4), neuroblastoma (3), and miscellaneous tumors (18). Treatment was generally well tolerated; most common toxicities were hematologic. Twenty-four (25%) patients completed 27 weeks therapy without progression, including HGG: 1 (5%), ependymoma: 7 (37%), LGG: 7 (58%), medulloblastoma/PNET: 1, neuroblastoma: 1, and miscellaneous tumors: 7 (39%). Best response was complete response (one patient with medulloblastoma), partial response (12), stable disease (36), progressive disease (47), and inevaluable (1). Baseline serum thrombospondin levels were significantly higher in patients successfully completing therapy than in those who progressed (P = 0.009). Conclusion: The 5-drug regimen was well tolerated. Clinical activity was demonstrated in some but not all tumor strata.
MeSH term(s)	Adolescent ; Adult ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Celecoxib ; Child ; Child, Preschool ; Cyclophosphamide/administration & dosage ; Etoposide/administration & dosage ; Female ; Fenofibrate/administration & dosage ; Follow-Up Studies ; Humans ; Infant ; Male ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Neoplasms/drug therapy ; Neoplasms/pathology ; Neovascularization, Pathologic/drug therapy ; Prognosis ; Prospective Studies ; Pyrazoles/administration & dosage ; Sulfonamides/administration & dosage ; Survival Rate ; Thalidomide/administration & dosage ; Young Adult
Chemical Substances	Angiogenesis Inhibitors ; Pyrazoles ; Sulfonamides ; Thalidomide (4Z8R6ORS6L) ; Etoposide (6PLQ3CP4P3) ; Cyclophosphamide (8N3DW7272P) ; Celecoxib (JCX84Q7J1L) ; Fenofibrate (U202363UOS)
Language	English
Publishing date	2013-10-04
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2131448-2
ISSN	1545-5017 ; 1545-5009
ISSN (online)	1545-5017
ISSN	1545-5009
DOI	10.1002/pbc.24794
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Search results

Search options

Article: The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.

More links

Kategorien

Order via subito

Article ; Online: Attributable costs of central line-associated bloodstream infections in a pediatric hematology/oncology population.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article: Immunotherapy for Epstein-Barr virus-associated tumors.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Idiopathic thrombocytopenic purpura complicated by an intracranial hemorrhage secondary to an arteriovenous malformation.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito